Liposome and sodium cromoglycate compositions, and methods for their preparation

Claim 2

A pharmaceutical composition comprisinc liposomes and sodium cromoglycate.

Claim 3

An aqueous suspension comprising sodiurr cromoglycate partitioned between a free aqueou; phase and a liposome phase.

Claim 4

An aqueous suspension comprising sodiurr cromoglycate partitioned between a free aqueou; phase and a liposome phase.

Claim 5

A composition according to Claim 1 or 2 wherein the liposomes have a diameter betweer 100 nm and 10 pm.

Claim 6

A composition according to any one of the preceeding Claims wherein the liposome; comprise one or more natural or synthetic lecithins.

Claim 7

A composition according to Claim 4, whereir the lecithin, or mixture of lecithins, has a phase transition temperature in the range 35―45°C.

Claim 8

A composition according to Claim 4 or Clairr 5 wherein the liposomes contain one or more additional components selected from cholesterol cholesterol stearate and a negatively or positively charged component.

Claim 9

A composition according to any one of the preceding Claims, wherein the ratio by weight o sodium cromoglycate to lipid is from 0.01 to 100

Claim 10

An aqueous suspension according to any one of Claims 2 to 7, wherein the total concentratior of sodium cromoglycate is from 0.01 to 50 mg/ml

Claim 11

A composition according to any one of the preceding Claims, wherein the percentage o sodium cromoglycate associated with th l liposomes is from 2 to 35% w/w.

Claim 12

A method of making a pharmaceutica composition according to Claim 1 or Claim 2 which comprises dispersing a thin film of lipid ir an aqueous solution of sodium cromoglycate.

Claim 13

An aqueous suspension comprising a tota concentration of from 0.1 to 20 mg/ml sodiun cromoglycate partitioned between an aqueous phase and a liposome phase, the liposome phase comprising one or more of the lecithins di (tetradecanoyl)phosphatidylcholine, di - (hexa decanoyl)phosphatidylcholine or di - (octa decanoyl)phosphatidylcholine, wherein th l concentration of the lecithin dispersed in th l aqueous phase is from 1 to 30 mg/ml and th l percentage of sodium cromoglycate associate with the liposomes is from 2 to 35% w/w.

Claim 14

An aqueous suspension comprising a tota concentration of from 0.1 to 20 mg/ml sodiun cromoglycate partitioned between an aqueous phase and a liposome phase, the liposome phase comprising one or more of the lecithins di (tetradecanoyl)phosphatidylcholine, di - (hexa decanoyl)phosphatidylcholine or di - (octa decanoyl)phosphatidylcholine, wherein th l concentration of the lecithin dispersed in th l aqueous phase is from 1 to 30 mg/ml and th l percentage of sodium cromoglycate associate with the liposomes is from 2 to 35% w/w.